Avacta Group PLC (LSE:AVCT) has spent the past year turning itself into a pure-play oncology company, and the next six months will show whether that bet pays off. The London-listed biotech now has US regulatory agreement on a single pivotal trial for its lead drug faridoxorubicin, a second-generation candidate in the clinic, and a stated preference to fund the next step through a partner rather than its own shareholders.

The key question is timing. Avacta said in May 2026 that its cash runway stretches only into early Q1 2027, and its accounts flag a material uncertainty over going concern. With first AVA6103 data promised for late 2026 and partnering talks unsigned, the gap between scientific progress and financial security is what could trigger the next big move in the shares.

FDA agrees pivotal trial design as bond repayments are accelerated

The most consequential recent news came on 25 June 2026, when Avacta announced that the US Food and Drug Administration had agreed the design of a pivotal trial for faridoxorubicin (AVA6000) in salivary gland cancer: a single study in first- and second-line patients, with progression-free survival as the sole primary endpoint, as the basis for full approval. The trial is expected to start once Phase 1b data mature.

Chief executive Christina Coughlin said the "constructive discussions with the FDA have resulted in a clear path forward" but stressed that the company is "committed to progressing faridoxorubicin into further clinical development only with the support of a partner".

The same day, data presented at the BIO International Convention showed four confirmed partial responses and eight minor responses among 32 salivary gland cancer patients in the pivotal-study population, with median progression-free survival not yet reached.

On 9 July 2026 Avacta settled an accelerated quarterly Amortisation payment of £3.67m on its convertible bond, comprising £2.4m of principal plus interest and fees, in cash rather than shares, cutting remaining principal to £16.8m. The cash came from an oversubscribed £9m placing on 5 June 2026 at 70p per share, priced at nil discount and led by an undisclosed institutional cornerstone investor, with the stated purpose of repaying deferred bond obligations and limiting dilution.

A drug-delivery platform aimed at doxorubicin's toxicity problem

Avacta is a clinical-stage life sciences company based in London, with clinical programmes in the US and Europe. Its pre|CISION technology uses a peptide linker cleaved by fibroblast activation protein (FAP), an enzyme abundant in the tumour microenvironment but rare in healthy tissue, to release potent chemotherapy payloads inside tumours while sparing the rest of the body.

Gen One is faridoxorubicin, a FAP-activated form of doxorubicin, in trials for salivary gland cancer, soft tissue sarcoma and triple-negative breast cancer. Gen Two is AVA6103, which delivers the topoisomerase inhibitor exatecan and dosed its first patient in the FOCUS-01 Phase 1 trial on 31 March 2026. Gen Three, AVA6207, remains preclinical.

The company no longer has a meaningful commercial business, having sold Launch Diagnostics in March 2025 for £12.9m upfront and Coris BioConcept in August 2025 for £2.15m upfront. Continuing Revenue was just £0.11m in 2025, so Avacta's income will come, if at all, from licensing and partnering.

FY2025 results: £37m loss, £16.9m cash and a going-concern warning

Unaudited preliminary results for the year to 31 December 2025, published on 19 May 2026, show the cost of that strategy. Research and Development spending from continuing operations rose to £18.76m from £14.27m, while administrative expenses fell to £10.03m from £12.05m as 2024's one-off restructuring costs dropped out.

The operating loss from continuing operations narrowed slightly to £30.69m from £32.56m, but loss before tax widened to £36.84m from £28.98m, reflecting finance costs linked to the convertible bond. Total loss after tax including discontinued operations was £38.61m, against £52.84m in 2024. Basic loss per share from continuing operations was 9.27p (2024: 8.54p).

Cash at 31 December 2025 stood at £16.9m, up from £12.9m a year earlier, after £22.5m of net Equity proceeds and £10.0m of net disposal proceeds. Convertible Bond principal outstanding at year end was £20.4m, and net Assets had shrunk to £2.48m from £9.28m.

Crucially, the directors disclosed a material uncertainty over going concern, stating there are "currently no agreements in place and there is no certainty that funds will be raised within the appropriate timeframe", while expressing confidence that funding will be forthcoming. Including the March 2026 placing of £10m at 63p and the June raise, Avacta says it has raised £41.5m over 18 months, extending runway into early Q1 2027. No Dividend is paid.

What could drive the stock next?

Initial clinical data from the FOCUS-01 trial of AVA6103 are expected in late H2 2026; chairman Shaun Chilton called the coming nine to twelve months "crucial" because this is the first human test of the Gen Two platform. A further faridoxorubicin update was flagged for a Q3 2026 medical congress.

Partnering is the other obvious trigger. Avacta has repeatedly said its assets are attracting interest from multiple parties, and management has made a deal a precondition for the pivotal salivary gland study. A licensing agreement with upfront cash would validate the platform and address the funding gap in one stroke.

Interim results for the six months to 30 June 2026, which last year arrived on 30 September, should give an updated cash figure and show how much of the bond remains exposed to acceleration by the bondholder.

Risks investors should watch

Funding is the central risk. With runway into early Q1 2027 and an operating loss above £30m a year, Avacta will need a Partnership or further equity within months. Shares in issue rose to roughly 469 million after the June placing, so further dilution is a live consideration if a partner does not materialise.

The convertible bond adds a second layer: although principal has fallen to £16.8m, the bondholder can accelerate quarterly payments, and settlement in shares would dilute holders further. Clinical risk is inherent. Faridoxorubicin's data come from an open-label Phase 1 study without a control arm, median progression-free survival is immature, and AVA6103 has no human efficacy data yet. Salivary gland cancer is a rare indication, so commercial value depends on a partner's appetite for a niche product, and with almost no revenue Avacta has nothing to cushion setbacks.

Outlook

Avacta enters the second half of 2026 with a clearer regulatory path than at any point in its history, a lead asset showing durable disease control in a hard-to-treat cancer, and a second candidate in the clinic. Against that sits a Balance Sheet the board acknowledges cannot carry the company much beyond early 2027 without new money.

Investors should watch for the late-2026 AVA6103 readout, any partnering agreement for faridoxorubicin, the H1 2026 interim results and the cash position they reveal, and further activity on the convertible bond. Which of those arrives first is likely to decide the direction of the next big move.